Laerdal Million Lives Fund

Laerdal Million Lives Fund

The Laerdal Million Lives Fund extends the mission of Laerdal Medical, the Norwegian-founded global leader in CPR training manikins and emergency medical equipment. While the Laerdal family's operating company has been saving lives since 1960 through products like the Resusci Anne and the first commercially available automated external defibrillator, the Million Lives Fund represents a structural decision to accelerate that mission through growth-stage venture capital. The fund is anchored by Laerdal Medical's balance sheet, giving it a patient, impact-aligned capital base that does not face the LP redemption cycles of traditional venture funds. The fund targets later-stage investments in digital health and medical device companies, with a focus on maternal and newborn health, emergency care, and trauma. Its mandate prioritizes interventions where clinical data can quantify lives saved—a bar that steers the portfolio away from wellness apps and into regulated, evidence-backed technologies. The firm typically leads or co-leads rounds in the $10 million to $50 million range, acting as a strategic investor that can open doors in hospital systems and global health organizations. The fund's thesis aligns with Laerdal Medical's distribution footprint across more than 100 countries, though specific portfolio company names remain largely undisclosed in public filings. The fund operates from San Francisco, positioning itself in the center of health-tech venture capital while maintaining ties to Laerdal Medical's global operations. The team combines venture investors with clinicians and global health experts—a hybrid structure uncommon in health-tech funds. This composition allows the fund to conduct clinical due diligence alongside commercial evaluation, screening for technologies that can both generate venture returns and meet the evidentiary standards of organizations like the World Health Organization and UNICEF. The fund's core structural differentiator is its relationship to a single mission-aligned corporate backer rather than a diversified LP base. That architecture permits investment timelines that extend beyond standard venture fund lifecycles, and it removes the tension between rapid exit pressure and the longer adoption cycles typical in hospital procurement and global health distribution. The governance structure places primary investment authority with the San Francisco-based partnership, with strategic alignment maintained through board-level coordination with Laerdal Medical and the Laerdal Foundation.